iSpecimen Inc. Files S-1 Registration Statement
Ticker: ISPC · Form: S-1 · Filed: Aug 20, 2025 · CIK: 1558569
Sentiment: neutral
Topics: sec-filing, s-1, registration-statement
TL;DR
iSpecimen filed an S-1, looks like they're going public or raising cash.
AI Summary
iSpecimen Inc. filed an S-1 registration statement with the SEC on August 20, 2025. The company, incorporated in Delaware, is in the commercial physical & biological research sector. Its principal executive offices are located at 8 Cabot Road, Suite 1800, Woburn, MA 01801, with a business phone number of (781) 301-6700. Katharyn Field is listed as President.
Why It Matters
This S-1 filing indicates iSpecimen Inc. is preparing to offer securities to the public, which could lead to significant capital infusion or changes in its ownership structure.
Risk Assessment
Risk Level: medium — An S-1 filing is a preliminary step for a company going public or issuing new securities, which inherently carries market and execution risks.
Key Numbers
- 333-289725 — SEC File Number (Identifies the specific registration filing with the SEC.)
- 08101 — ZIP Code (Part of the company's principal business address.)
Key Players & Entities
- iSpecimen Inc. (company) — Registrant
- August 20, 2025 (date) — Filing Date
- 8 Cabot Road, Suite 1800, Woburn, MA 01801 (location) — Principal Executive Offices
- 781-301-6700 (phone_number) — Business Phone
- Katharyn Field (person) — President
- 333-289725 (registration_number) — SEC File Number
FAQ
What is the purpose of this S-1 filing for iSpecimen Inc.?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public, indicating potential public offering or capital raise.
When was this S-1 filing submitted to the SEC?
The S-1 filing was submitted to the SEC on August 20, 2025.
Where are iSpecimen Inc.'s principal executive offices located?
iSpecimen Inc.'s principal executive offices are located at 8 Cabot Road, Suite 1800, Woburn, MA 01801.
Who is listed as the President of iSpecimen Inc. in this filing?
Katharyn Field is listed as the President of iSpecimen Inc.
What is the SEC File Number for this iSpecimen Inc. registration statement?
The SEC File Number for this registration statement is 333-289725.
Filing Stats: 4,426 words · 18 min read · ~15 pages · Grade level 17.4 · Accepted 2025-08-20 15:40:43
Key Financial Figures
- $0.0001 — 9,828 shares of common stock, par value $0.0001 per share, of iSpecimen, Inc., held by
- $0 — t a nominal exercise price per share of $0.0001, without expiration, all of which
- $1.11 — ted sale price for our common stock was $1.11 per share. We are an "emerging growth
Filing Documents
- ea0253778-s1_ispecimen.htm (S-1) — 2080KB
- ea025377801ex5-1_ispecimen.htm (EX-5.1) — 8KB
- ea025377801ex23-1_ispecimen.htm (EX-23.1) — 2KB
- ea025377801ex23-2_ispecimen.htm (EX-23.2) — 3KB
- ea025377801ex-fee_ispecimen.htm (EX-FILING FEES) — 13KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 4KB
- ex5-1_001.jpg (GRAPHIC) — 5KB
- ex23-2_001.jpg (GRAPHIC) — 23KB
- ex23-2_002.jpg (GRAPHIC) — 9KB
- 0001213900-25-078951.txt ( ) — 9364KB
- ispc-20250630.xsd (EX-101.SCH) — 71KB
- ispc-20250630_cal.xml (EX-101.CAL) — 90KB
- ispc-20250630_def.xml (EX-101.DEF) — 411KB
- ispc-20250630_lab.xml (EX-101.LAB) — 670KB
- ispc-20250630_pre.xml (EX-101.PRE) — 440KB
- ea0253778-s1_ispecimen_htm.xml (XML) — 1158KB
- ea025377801ex-fee_ispecimen_htm.xml (XML) — 4KB
Use of Proceeds
Use of Proceeds 33 Dividend Policy 33
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 33
Business
Business 47 Management 61
Executive Compensation
Executive Compensation 66 Certain Relationships and Related Party Transactions 73 Principal Stockholders 74
Description of Securities
Description of Securities 75 August 2025 Private Placement 77 Selling Stockholders 78 Plan of Distribution 79 Legal Matters 80 Experts 80 Where You Can Find More Information 80 Index to Financial Statements F-1 i ABOUT THIS PROSPECTUS This prospectus describes the general manner in which the Selling Stockholders may offer from time to time the Shares and Warrant Shares. You should rely only on the information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation of an offer to purchase, the common stock offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should not assume that the information contained in this prospectus, any prospectus supplement or amendments thereto, as well as information we have previously filed with the U.S. Securities and Exchange Commission (the "SEC"), is accurate as of any date other than the date on the front cover of the applicable document. If necessary, the specific manner in which the shares of common stock may be offered and sold will be described in a supplement to this prospectus, which supplement may also add, update or change any of the information contained in this prospectus. To the extent there is a conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information in such prospectus
forward-looking statements include statements relating to
forward-looking statements include statements relating to: our ability to enter into contracts with healthcare providers to gain access to specimens, subjects, and data on favorable terms; our ability to obtain new customers and keep existing customers; development of our technology to adequately keep pace to support expansion of our existing line of business or our entry into new lines of businesses; market adoption rate of our marketplace technology; our ability to continue to expand outside of the United States in compliance with local laws and regulations; our business model generally and our utilization of the proceeds from this offering; acceptance of the products and services that we market; the viability of our current intellectual property; government regulations and our ability to comply with government regulations; our ability to retain key employees; adverse changes in general market conditions for biospecimens; our ability to generate cash flow and profitability and continue as a going concern; our future financing plans; and our ability to adapt to changes in market conditions which could impair our operations and financial performance. These forward-looking statements involve numerous risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results of operations or the results of other matters that we anticipate could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Business," "Regulation" and other sections included or incorporated by reference in this prospectus. You should thoroughly read this prospectus and the documents incorporated herein by re